You are here: Industry Insights > Chiesi

News List

Chiesi USA Announces New Organizational Leadership for the Chiesi Foundation americanpharmaceuticalreview
May 14, 2021
Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), announced that Maria Paola Chiesi was appointed President of the Chiesi Foundation, a non-profit organization established in 2005 ...
Chiesi's Raxone recommended for use within NHS Wales pharmatimes
April 29, 2021
Chiesi’s rare disease medicine Raxone has been recommended for use within NHS Wales for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).
Chiesi Group Receives European Marketing Authorization for Trimbow® Inhalation Powder americanpharmaceuticalreview
April 22, 2021
Chiesi, an international research-focused healthcare group has announced that the European Commission has granted the marketing authorization for Trimbow® inhalation powder delivered through NEXThaler (beclometasone dipropionate, formoterol fumarate ...
Chiesi launches pilot inhaler recycling scheme in the UK pharmatimes
February 20, 2021
Italian pharma company Chiesi has launched a pilot scheme in Leicestershire, UK which will aim to make disposing of and recycling inhalers easier.
EU approves Chiesi’s triple combination asthma therapy Trimbow pharmatimes
February 02, 2021
The European Commission (EC) has approved a marketing authorisation for Chiesi Group’s triple combination asthma therapy Trimbow (beclometasone/formoterol/glycopyrronium).
Chiesi Group Receives EMA for Triple-Combination Therapy Asthma americanpharmaceuticalreview
February 02, 2021
Chiesi announced the European Commission has granted the marketing authorization for Chiesi extrafine triple therapy combination ICS/LABA/LAMA in a single inhaler, for the treatment of asthma.
Chiesi USA Announces General Manager, Chief Executive Officer Appointment americanpharmaceuticalreview
December 30, 2020
Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A., has announced the appointment of Jon Zwinski as General Manager and Chief Executive Officer of Chiesi USA to advance the company’s global therapeutic efforts. Effective Jan. 1, 2021 ...
Protalix BioTherapeutics, Chiesi Global Announce BLA Acceptance of Pegunigalsidase Alfa americanpharmaceuticalreview
August 14, 2020
Protalix BioTherapeutics together with its development and commercialization partner Chiesi Global Rare Diseases, a unit of Chiesi, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted ...
Chiesi Receives FDA Approval for Ferriprox Twice-a-Day Tablets americanpharmaceuticalreview
May 27, 2020
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici, announced the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets.
Environmentally friendly pressurised Metered Dose Inhaler to be developed europeanpharmaceuticalreview
December 09, 2019
A pharmaceutical company has announced its intention to create a pressurised Metered Dose Inhaler that will reduce the carbon footprint of the drug delivery system.

Previous page 1 2 Next page